REPLIGEN CORP Business Acquisition, Transaction Costs
REPLIGEN CORP (RGEN) had Business Acquisition, Transaction Costs of $2.70 million as of 2022-12-31, per its 10-K/A filed 2024-11-18.
Financial Statements › Notes
us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts · last filed 2024-11-18
- 2022-12-31: Business Acquisition, Transaction Costs $2.70M.
- 2022-09-30: Business Acquisition, Transaction Costs $2.20M.
- 2022-06-30: Business Acquisition, Transaction Costs $1.60M.
- 2021-12-31: Business Acquisition, Transaction Costs $300.00K.
| Period end | Business Acquisition, Transaction Costs |
|---|---|
| 2022-12-31 | $2.70M 10-K/A · filed 2024-11-18 |
| 2022-09-30 | $2.20M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $1.60M 10-Q · filed 2022-08-02 |
| 2021-12-31 | $300.00K 10-K/A · filed 2024-11-18 |
| 2019-12-31 | $4.00M 10-K · filed 2021-02-24 |
| 2019-03-31 | $1.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |